ClinicalTrials.gg
CompletedNCT02024230REWRAPSUpdated Jan 3, 2023

Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS)

A Phase 4 interventional study of Rivaroxaban or Warfarin in Coronary Artery Disease, Atrial Fibrillation and Stroke, sponsored by Fujita Health University. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-01-03.

Sponsored by Fujita Health University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Coronary Artery Disease with a site in Japan — 12 open to participants now, 21 under way, 2 of them phase 3. Coronary Artery Disease · Japan.

Enrollment
46th of 100
500 · median 445
Started
2014
with 11 others
Phase 4
36 of 134
1 open now
Registered
68th of 134
by date

Among the 134 studies in Coronary Artery Disease with a site in Japan, this one is the 46th largest by enrollment of the 100 interventional ones that give a count, is one of 12 that started in 2014, is one of 36 in phase 4, and was the 68th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

12 of the 134 studies in Coronary Artery Disease with a site in Japan are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Coronary Artery Disease with a site in Japan, or all of them as a file.
02

Study summary

Antiplatelet therapy is indispensable for the prevention of stent thrombosis in patients who underwent coronary artery stenting. Similarly, anticoagulant therapy is essential for the prevention of cardiogenic embolism including cerebral infarction in AF patients. However, the combined antithrombotic therapy has been reported to increase the risk of major bleeding for AF patients after coronary stenting, New anticoagulant drugs that hardly interact with other drugs and do not need frequent blood tests have become commonly used. The purpose of this study is to assess the hypothesis that Rivaroxaban is non-inferior to Warfarin in the efficacy and safety for AF patients after coronary stenting

03

Conditions studied

  • Coronary Artery Disease
  • Atrial Fibrillation
  • Stroke
  • Fetal Blood Loss
  • Major Bleeding
  • All Cause Mortality
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Clinically stable atrial fibrillation (AF) patients who underwent coronary artery stenting more than one year ago and are treated or are scheduled to be treated with anticoagulant drug (regardless of the type of stents and AF).

Those who are willing to cooperate with us in the study. Those who can sign the document that is approved by the ethics committee of the medical institution participating in the study.

Exclusion criteria

Exclusion Criteria:

Those in whom the package inserts state anticoagulant drugs are for use Those who are scheduled to undergo percutaneous coronary intervention or catheter ablation for AF. Those who have to continuously undergo dual antiplatelet due to a past history of stent thrombosis during the distant stage after stenting. Those who have undergone prosthetic valve replacement for valvular disease. Those who the physician in charge judges are ineligible for the study due to serious pathological conditions. Those who are not willing to participate in the study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (actual)

Study arms

  • Active comparator
    Rivaroxaban

    Patients were treated over a median of 4.75 years with either rivaroxaban (10 mg once daily for patients with a creatinine clearance of 15-49 mL/min or 15 mg once daily for patients with a creatinine clearance ≥50 mL/min)

    Drug: Rivaroxaban or Warfarin

  • Active comparator
    Warfarin

    The dose of warfarin can be controlled with dose adjustment to achieve a target international normalized ratio \[INR\] of 2.0-3.0 or in patients aged \>70 years and having a high bleeding risk, a target INR of 1.6-2.6) according to the guideline of Japanese Circulation Society based on the following paper (Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J 2013;77(9):2264-70.)

    Drug: Rivaroxaban or Warfarin

Interventions

  • DrugRivaroxaban or Warfarin

    a multi-center, prospective, non-randomized, open-label, physician-initiated interventional allocation study either rivaroxaban or warfarin

06

What researchers measure

Primary outcomes

  1. a composite of adverse events

    cardiac or stroke death, non-fatal myocardial infarction, non-fatal stroke, coronary artery revascularization (percutaneous coronary intervention or coronary artery bypass graft), and systemic embolism

    Time frame: 3 years

  2. major bleeding

    BARC 3 and 5

    Time frame: 3 years

  3. Net Adverse Clinical Event (NACE)

    a composite of all-cause death and major bleeding

    Time frame: 3 years

Secondary outcomes

  1. all-cause death

    Time frame: 3 years

  2. admission due to congestive heart failure

    Time frame: 3 years

  3. fatal arrhythmia

    Time frame: 3 years

  4. electrocardiographic findings

    rhythm, ST change, Q wave abnormality, QRS duration, QT interval, QTc interval, the presence of supraventricular premature contraction (SVPC), the presence of ventricular premature contraction (VPC)

    Time frame: 3 years

  5. cardiac ultrasound findings

    left atrial dilatation (LAD), left ventricular end-diastolic diameter (LVDd), left ventricular end-systolic diameter (LVDs), E/A, E/E', tricuspid regurgitation pressure gradient (TRPG), LV wall abnormality

    Time frame: 3 years

  6. each cardiovascular event used for the primary efficacy outcome measures

    Time frame: 3 years

  7. non-major clinical relevant bleeding

    Time frame: 3 years

  8. cardiac or stroke death

    Time frame: 3 years

  9. non-fatal myocardial infarction

    Time frame: 3 years

  10. non-fatal stroke

    Time frame: 3 years

  11. coronary artery revascularization (percutaneous coronary intervention or coronary artery bypass graft)

    Time frame: 3 years

  12. systemic embolism

    Time frame: 3 years

07

Study locations

1 site
  • Yukio Ozaki
    Nagoya, Aichi 461-0021, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Dec 2018, 59 months.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 59 months is above that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2013
First posted
Dec 31, 2013
StartActual
Jan 2014
Primary completionActual
Dec 2018
CompletionActual
Dec 2022
Last update
Jan 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02024230
Lead sponsor
Fujita Health University
Responsible party
Yukio Ozaki (Department of Cardiology, Fujita Health University, Fujita Health University) — Principal investigator
First posted
Dec 31, 2013
Start date
Jan 2014
Primary completion
Dec 2018
Completion
Dec 2022
Last update
Jan 3, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion